59 results about "Lacrimal gland duct" patented technology

Described herein are polymer formulations for facilitating electrical stimulation of nasal or sinus tissue. The polymer formulations may be hydrogels that are prepared by a UV cross-linking process. The hydrogels may be included as a component of nasal stimulator devices that electrically stimulate the lacrimal gland to improve tear production and treat dry eye. Additionally, devices and methods for manufacturing the nasal stimulators, including shaping of the hydrogel, are described herein.

The invention relates to a method of insulin eye drops for treating dry eye syndrome due to any and all etiological factors (Keratoconjunctivitis sicca), including Sjogren's syndrome, Meibomian gland dysfunction (MGD) and other glandular malfunction in the eye lids, lacrimal glands, cornea, conjunctiva, and exposed scleral surface of the eye. It is treated with Insulin and / or IGF-I with or without known anti-dry eye syndrome therapeutic, pharmaceutical, biochemical and biological agents or compounds.

A non-invasive apparatus and method for increasing saliva and tear production from the salivary and lacrimal glands with the application of high frequency low intensity ultrasound. An ultrasound transducer coated with connecting gel placed in contact with the facial tissues transmitting 1.5 MHz frequency ultrasound pressure waves into the tissues and into the glands. The time-averaged intensity of the ultrasound pressure waves is typically limited to approximately 30 milliwatts per square centimeter to avoid tissue heating.

The present invention provides a bioartificial lacrimal gland which contains at least one unit that includes (a) a permeable housing having an interior and an exterior; (b) an outlet connecting the housing interior to the housing exterior; and (c) a population of lacrimal epithelial cells within the housing interior.

An ophthalmic composition for artificial tears useful for treating dry eye symptoms or for general eye protection. The composition includes a physiologically balanced salt solution and one or more anti-oxidative ingredients which collectively confer on said ophthalmic composition a total antioxidant capacity as a FRAP value of greater than 100 μmol / l, preferably greater than 150 μmol / l. The composition also has peak UV absorption in the range of 200-350 nm. Suitable anti-oxidative ingredient includes ascorbate (ascorbic acid), urate (uric acid), cysteine, glutathione, tyrosine, lactoferrin, transferrin, albumin, caeruloplasmin and lacrimal gland peroxidase.

Swimming goggles include left and right frame bodies installed with lenses, a connecting element, and protective pads and head strap bases. The left and right frame bodies each has inner and outer peripheral faces. The protective pads each has a connecting portion having a connecting face and an abutting face. Lip portions are respectively formed along the inner peripheral faces of the left and right frame bodies. The connecting faces integrally encompass the lip portions. The abutting faces are inclined with respect to face portions corresponding to an area above the eye socket and adjacent to an eyebrow, a side portion of a nose bridge adjacent to lacrimal gland at an inner side portion of the eye socket, an area adjacent to an under-eye bag below the eye socket, and an outer eye corner with respect to an outer side portion of the eye socket adjacent to a temple.

A composition for preventing or treating an eye disease includes adiponectin as an active ingredient. Adiponectin as an active ingredient is eventually revealed to show prevention or therapeutic efficacies for eye diseases such as dry eye (syndrome), inflammatory eye disease and side effects due to the use of contact lenses by promoting tear secretion, alleviating ocular surface irregularities, decreasing inflammatory cytokines on the ocular surface and lacrimal gland, and increasing conjunctival goblet cell density. In addition, the composition having eye contact lubrication effects may be used as cleaners or lubricants for preventing non-bacterial inflammation due to wearing contact lenses.

The present invention relates to a novel lacrimal gland protein (designated lacritin) and the nucleic acid sequences encoding that protein. Lacritin has activity as a growth factor on both human corneal epithelial cells and on the lacrimal acinar cells that produce it. Accordingly, one embodiment of the present invention is directed to the use of lacritin to treat Dry Eye and other disorders requiring the wetting of the eye.

The invention provides a self-adaption eye physical therapy device which comprises an eyeshade body. The eyeshade body comprises an outer layer, a circuit board layer, a liquid storage layer, an atomizing layer and an inner layer which are sequentially arranged from top to bottom. Ultrasonic atomizing and infrared radiating are combined to act on eye skin, the absorption of the eye skin to medicines is enhanced and promoted, the movement of the eye skin and subcutaneous tissue cells is accelerated, the blood circulation of the eye skin is accelerated, the blood supply of periorbital local tissue is increased, the adjusting function of musculus ocularis is enhanced, the elasticity of musculus ocularis is restored, the secretion of lacrimal glands is promoted, eyes are kept moist, eye fatigue is relieved and eliminated, meanwhile the temperature and humidity of the eyes in the physical therapy process are effectively controlled, the eye skin tissue is protected, the power consumption of the device is reduced, and the self-adaption eye physical therapy device is small in size and quite suitable for an individual or a family.

The invention relates to animal feed, particularly a dry type food used for aged pet dogs. The food comprises following components by mass: 1-2% of a black sesame extract product, 2-3% of an oat extract product, 1-2% of a barbary wolfberry fruit extract product, 0.5-1% of a honeysuckle bud and flower extract product, 0.5-1% of a wild chrysanthemum flower extract product, 5-10% of egg white powder, 1-3% of bovine bone powder, 2-5% of pig liver, 1-3% of threonine, 1-6% of calcium lactate, 0.5-1.5% of lysine, 40-60% of meat, 2-5% of vegetables, 1-6% of potassium sorbate, 1-3% of deep-sea fish oil, 0.5-1.5% of animal oil, 0.5-1.5% of a carrot extract product, 3-6% of gelatin, 0.5-0.8% of toosendanin, 1-2% of insect proteins, 1-5% of vitamin C and 1-3% of a food additive, with the balance being corn flour. The food is capable of preventing gastric distention, reducing the occurrence rate of cardiovascular disease, improving baldness, reducing lacrimal gland and nasolacrimal duct abnormity, lowering blood pressure and preventing thrombosis.

The invention discloses a traditional Chinese medicine composition formula for treating calculosis, composed of desmodium, digua fig stem and leaf, lygodium japonicum, China fir, tuckahoe, corn silk, weeping willow and fringed pink. The pharmaceutical composition has the effects on clearing away heat, promoting diuresis, promoting blood circulation, relieving pain, removing calculus and inducing diuresis, can be used for treating different sizes of calculuses in hepatic ducts, parotid gland, lacrimal gland, bile ducts and gall bladder and urethral calculus in kidney, nephric ducts, bladder and the like, also can be used for treating calculus pain, retention of urine and other related complications, and is a relatively ideal clinical therapeutic medicament for calculosis. In addition, the medicament is not found having any toxic side effects and has certain preventive effects on all kinds of calculosis if a small dose of medicament is taken for a long time.

The invention provides an external traditional Chinese medicinal composition for treating xerophthalmia and a preparation method thereof. The external traditional Chinese medicinal composition for treating the xerophthalmia is prepared from the following raw materials: wolfberry, chrysanthemum, salviae miltiorrhizae, cortex phellodendri, pearl powder, borneol and menthol. The external traditional Chinese medicinal composition for treating the xerophthalmia has the advantages that pathological changes of lacrimal gland tissues of an experimental xerophthalmia mouse, lacrimal glands of which are damaged by injected pingyangmycin, in morphology can be obviously alleviated, quantity of tear fluid can be obviously increased, breakup time of a tear film is prolonged, and quantity of the tear fluid secreted by a normal domestic rabbit can be obviously increased.

Disclosed is an eye drop containing turmeric extract which is prepared from the following constituents (by weight ratio): turmeric extract 0. 15-0. 45, taurine 0. 07, sodium hyaluronate 0. 033, vitamin B6 0. 033, boracic acid 0. 8-1. 2, borax 0. 8-1. 2, polyoxyethylene hydrogenated castor oil 1. 5-4. 5 and balancing distilled water. The invention also relates to the process for preparing the eye drop, which contains the precursor of human body hormones, and is capable of facilitating auto-regulated hormones in human body, increasing lacrimal gland secretion, increasing eye cells vitality, improving eye microcirculation, and alleviating symptoms of dry-eye patients.

The invention provides a new application of a traditional Chinese medicinal composition and in particular relates to an application of a traditional Chinese medicinal composition in preparation of a medicine used for treating xerophthalmia, and raw materials of the traditional Chinese medicinal composition comprise wolfberry, chrysanthemum, salviae miltiorrhizae, cortex phellodendri, borneol, pearl powder and menthol. The traditional Chinese medicinal composition has the advantages that pathological changes of lacrimal gland tissues of an experimental xerophthalmia mouse, lacrimal glands of which are damaged by injected pingyangmycin, in morphology can be obviously alleviated, quantity of tear fluid can be obviously increased, breakup time of a tear film is prolonged, and quantity of the tear fluid secreted by a normal domestic rabbit can be obviously increased; and meanwhile, the traditional Chinese medicinal composition has obvious anti-inflammation and anti-oxidation effects.

The invention puts forward eye-protecting health care plaster, which comprises active ingredients and absorption-accelerating ingredients. The eye-protecting health care plaster comprises the following ingredients in parts by weight: 2-8 parts of flos buddlejae, 3-8 parts of flos chrysanthemi indici, 5-15 parts of herba menthae, 5-12 parts of ginseng radix, 5-12 parts of stigma croci, 5-12 parts of spica prunellae, 2-10 parts of folium mori, 4-15 parts of semen cassia, 5-15 parts of semen plantaginis, 1-10 parts of radix saposhnikoviae, 1-5 parts of radix salviae miltiorrhizae, 1-6 parts of rhizoma coptidis, 2-7 parts of phellodendri chinensis cortex and 5-13 parts of herba equiseti hiemalis. The invention provides the eye-protecting health care plaster, the prepared eye plaster has mild performance and provides good protection for the eye skin, and meanwhile, the eye-protecting health care plaster has the functions of increasing the blood flow speed of the periphery of eyes, eliminating bulbar conjunctival microcirculation disturbance of the eyes, preventing from forming microcirculation disturbance and effectively alleviating asthenopia. Finally, the eye-protecting health care plaster can obviously improve the ultramicrostructure of lacrimal gland tissues, stimulate the lacrimal gland to increase secretion volume and further improve the stability of the lacrimal film.

The invention discloses a lacrimal passage washing device. The lacrimal passage washing device comprises an injector, an injection head, an injection needle head, a needle head fixing part, a hard hemp catheter, and a catheter fixing part. The injection needle head is connected to the injection head through the needle head fixing part. The hard hemp catheter is sheathed outside the injection needle head, and the hard hemp catheter is fixed through the catheter fixing part. The injection needle head is a hard pipe. The hard hemp catheter is a hose. The lacrimal passage washing device is capableof effectively preventing the needle head from injuring a lacrimal gland by mistake in a washing process of the lacrimal passage, and effectively avoiding the cross infection generated in a repeatedusing process of the used hard hemp catheter in the washing process.

The present invention relates to the administration of Keratinocyte Growth Factor-2 (KGF-2) to stimulate proliferation of platelets and to increase levels of fibrinogen, albumin, globulin and total serum protein. Further, the present invention relates to administering KGF-2 to protect or treat the bladder and prostate. Moreover, the present invention relates to administering KGF-2 to stimulate growth of nasal, oral, and esophageal mucosa, lacrimal glands, salivary glands and Goblet cells.

The invention relates to a lacrimal gland stem cell as well as a culture system and a culture method for the lacrimal gland stem cell and relates to the field of cell engineering. According to the culture system for the lacrimal gland stem cell, disclosed by the invention, DMEM / F12 serves as a basal culture medium, and the following components are added to form a culture liquid: a cell culture additive, non-essential amino acids, L-alanyl-L-glutamine, mitogen activeated protein kinase / extracellular signal-regulated kinase signaling pathway ligand, fibroblast growth factors, a Wnt signaling pathway ligand, and a composition of ROCK signaling pathway inhibitors; and matrigel serves as a stereoscopic support. The culture method disclosed by the invention comprises the following steps: digesting lacrimal gland tissues of mice into single cells to be inoculated into matrigel, adding the cells into a lacrimal gland stem cell culture liquid after solidification, and performing primary culture. The lacrimal gland stem cells cultured by the method disclosed by the invention are high in quantity and capable of realizing stable and continuous passage, have an effect of restoring the lacrimalgland secretion effect, and can be used for effectively treating xerophthalmia.

This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

The invention relates to a keratoconjunctivitis sicca preventing and treating eye drop and a preparation and application method thereof. The keratoconjunctivitis sicca preventing and treating eye drop is composed of cyoloalliin, anthocyanin, dextranum, hydroxypropyl methyl cellulose, sodium chloride, potassium chloride, sodium borate, pH regulator and purified water. During application, the keratoconjunctivitis sicca preventing and treating eye drop can supplement water for eyes, form protective films on the surfaces of eyes and reduce water evaporation to effective relieve the symptoms caused by keratoconjunctivitis sicca such as dry eyes, and meanwhile, can stimulate secretion of lacrimal glands and increase the number of times of blinking; the cyoloalliin can inhibit secretion of inflammatory factors to release the clinical symptom of dry eyes and meanwhile fundamentally cure the keratoconjunctivitis sicca; besides, the keratoconjunctivitis sicca preventing and treating eye drop is free from preservatives, safe, non-irritative to eyes, high in long-term stability and applicable to wide application of prevention and treatment of various kinds of keratoconjunctivitis sicca.

The present invention relates to a novel lacrimal gland protein (designated lacritin) and the nucleic acid sequences encoding that protein. Lacritin has activity as a growth factor on both human corneal epithelial cells and on the lacrimal acinar cells that produce it. Accordingly, one embodiment of the present invention is directed to the use of lacritin to treat Dry Eye and other disorders requiring the wetting of the eye.

The invention provides an eye physiotherapy device, comprising an eye mask body, the eye mask body includes an outer layer, a circuit board layer, a liquid storage layer, an atomization layer and an inner layer, the outer layer, the circuit board layer, the The liquid storage layer, the atomization layer and the inner layer are arranged sequentially from top to bottom. The present invention combines ultrasonic atomization and infrared radiation to act on the skin of the eyes, enhances and promotes the absorption of drugs by the skin of the eyes, intensifies the movement of the skin of the eyes and subcutaneous tissue cells, accelerates the blood circulation of the eyelids, and increases the blood circulation of the local tissues around the eyes. Blood supply, enhance the regulation function of eye muscles, restore eye muscle elasticity, promote lacrimal gland secretion, keep eyes moist, relieve and eliminate eye fatigue, and its small size is very suitable for personal or family use.

The invention provides a hydrogel eye mask easy to apply and relates to the technical field of hydrogels. The hydrogel eye mask easy to apply comprises a substrate layer, a hydrogel layer attached tothe substrate layer, a gauze layer for fixing the hydrogel layer and a covering layer, wherein the covering layer is laid on the gauze layer, and the substrate layer, the hydrogel layer and the gauzelayer are separately provided with two eye exposure holes. The hydrogel eye mask further comprises an adhesion part connected with the substrate layer, and the side, in contact with the gauze layer, of the covering layer is provided with a smooth layer. The eye mask easy to apply does not easily drop, can improve the blood microcirculation of the subcutaneous tissue of the eyes, stimulates the secretion of lacrimal glands through cold sensation, and can prevent the secretion function of the lacrimal glands from deteriorating; the loss of the essence is reduced, and the utilization rate of theessence in the eye mask is improved; the amount of the essence contained in the eye mask is high, and the essence in the eye mask is easy to absorb.

The invention discloses a surgical operation method. A pupil and embolus fixing part are included, wherein a lacrimal gland catheter is mounted above a pupil; a lacrimal gland is mounted above the lacrimal gland catheter; an upper lacrimal punctum is mounted above one side of the pupil; an angle of eye medial is mounted below one side of the pupil; a lower lacrimal punctum is mounted on one side of the angle of eye medial; a main lacrimal duct is mounted on one side of the middle of the pupil; the main lacrimal duct is internally provided with a lacrimal sac; a naso-lacrymal duct is arranged inside the lacrimal sac; a silicone tube is arranged inside the naso-lacrymal duct; and the embolus fixing part is positioned below the silicon tube. By adopting the operation method, dirt accumulatedin a lacrimal passage cavity can be sufficiently flashed out from inside to outside, continuous cleanliness of the lacrimal passage cavity can be maintained, lacrimal passage inflammation reactions can be alleviated, the lacrimal passage cavity can be prevented from re-occurrence of adhesion and sealing, and thus the treatment effect can be improved.

The invention discloses a special lacrimal gland retractor for an ophthalmologic operation, which structurally comprises a liquid collecting rack wheel groove, nipper rod frames, battens, a cross-shaped sleeve rod seat, a piston rod and a finger pressing column cap. The special lacrimal gland retractor for the ophthalmologic operation achieves effects that the liquid collecting rack wheel groove is applied to be matched with the nipper rod frames, a frame rail annular groove and flow drawing brush frame bases are erected at the position of the eyelid by the nipper rod frame to adjust a thickness of care solution to avoid refraction and guarantee a thin layer to cover the eyeball and the pupil end so as to form an anti-interference operation effect of the care solution during the eye surgery; after the lacrimal gland position is effectively exposed,the lacrimal sac is subjected to precise knife feeding cutting, and an effective close-range detection deviation value is sensed inside by adiode fan base and a groove relay disc so as to facilitate the correction operation effect of a scalpel; the auxiliary promotion of a thin frame appliance for retracting the lacrimal gland when the eyelid and the eyeball are subjected to cushioning protection is improved; surgical eye closing is guaranteed to be rapidly completed; and internal solution is carded to form a postoperative retractingoperation timely closing maintenance effect.

The invention provides a stable dry-eye animal model. The dry-eye animal model is constructed through knocking out a gene AQP5 from an animal; and the knockout of the gene AQP5 means knocking out nucleotide fragments of a region 99589876-99594444 of a fifteenth chromosome of a mouse. The dry-eye mouse model provided by the invention is applied to screening or evaluating on effects of dry-eye treatment drugs. The AQP5<- / -> mouse model provided by the invention is high in repeatability and stable in model, researches on dry-eye pathological mechanism and drug intervention are facilitated, and influence on experimental results caused by other influencing factors can be avoided. Furthermore, the AQP5<- / -> mouse model provided by the invention emerges a characteristic change, i.e., reduced tearsecretion after birth, and after birth, lacrimal glands outside orbits emerge a pathologic characteristic, i.e., vacuolar degeneration; and the secretion of tears is free of obvious changes along with increase of ages and is free of sex difference.